Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 7
Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
Panelists discuss factors influencing the decision to continue adjuvant immunotherapy for patients achieving pathologic complete response (pCR) with pembrolizumab-containing therapy, weighing the benefits against risks and considering the role of biomarkers. They also explore sequencing decisions for patients with both BRCA mutations and early-stage triple-negative breast cancer (TNBC), focusing on the prioritization of PARP inhibition versus immunotherapy and situations where both may be recommended. Additionally, they discuss approaches to monitoring and managing immune-related adverse events, including baseline screening and ongoing management protocols.
Video content above is prompted by the following:
- Dr. Shatsky asks Dr. Degen: For patients achieving pCR with pembrolizumab-containing therapy, what factors influence your decision about adjuvant immunotherapy continuation? (31: 28 -
- How do you weigh the potential benefits against risks?
- What role do biomarkers play in this decision?
- Dr. Degen asks Dr. Shatsky: How do you approach sequencing decisions for patients with both BRCA mutations and early-stage TNBC? (33:51
- What factors guide your prioritization of PARP inhibition versus immunotherapy?
- Are there specific scenarios where you recommend both approaches?
- Dr. Shatsky asks Dr. Degen: Could you discuss your approach to immune-related adverse event monitoring and management?
- What is your protocol for baseline screening and ongoing monitoring?